Citations

Mayo Clinic

Showing 10 of 108522 citations.

Abstract We003: Identification of CircRNA-miRNA-mRNA Regulatory Network and Crucial Signaling Pathways Related to Cardiomyocyte Proliferation in Neonatal Mice
Tang, Ling , Nyarige, Verah , Li, Pengsheng , Zhu, Wuqiang, Zhu, Wuqiang

Circulation Research | October 9, 2024 | Volume: 135 | Issue: Suppl_1 | Pages: AWe003-AWe003

10.1161/res.135.suppl_1.we003 Get It

Introduction: Neonatal pig hearts exhibit remarkable regenerative capacity within two days post-birth. In this study, we propose that a comprehensive multiomics analysis encompassing circRNA, miRNA, and mRNA data from neonatal mouse hearts can unveil intricate circRNA-miRNA-mRNA relationships associated with cardiac regeneration. Our aim is to identify new novel circRNAs and miRNAs implicated in cardiomyocyte proliferation through leveraging multiomics analysis. Methods: Utilizing neonatal mouse hearts, we conducted circRNA, miRNA, and mRNA sequencing across four different postnatal days (P1, P3, P7, and P28; n=6, encompassing both males and females). We employed integrative bioinformatics analyses across distinct experimental designs (P1 vs P3, P1 vs P7, and P1 vs P28). Back splice junctions generated by CIRCexplorer2’s parse command was utilized to annotate sequenced circRNAs as known or novel. Validation of circRNA, miRNA, and mRNA expression levels was achieved through qRT-PCR, while protein expression levels were assessed via western blotting. Fluorescence in situ hybridization (FISH) technology was employed to determine circRNA localization. The functional significance of key genes involved in cardiomyocyte proliferation was assessed via siRNA-mediated knockdown of circRNAs and miRNAs, accompanied by cell cycle assessment using bioluminescence assay and immunostaining. Results: Intersection of differentially expressed target genes from circRNA, miRNA, and mRNA analyses at each experimental design facilitated the construction of circRNA-miRNA-mRNA regulatory networks, aiding in the development of cardiac regeneration-related regulatory networks and inference of novel relationships between circRNA, miRNA, and mRNA. Integrative bioinformatics analysis revealed significant alterations in circRNA-miRNA-mRNA expression profiles during postnatal cardiomyocyte maturation in mice. Pathway enrichment analysis identified several differentially expressed circRNAs enriched in cell division and proliferation-related pathways. qPCR and cell cycle studies identified 17 potential circRNAs associated with cardiomyocyte proliferation in mice, with knockdown of these circRNAs significantly impacting cardiomyocyte cell cycle. Conclusion: Our findings suggest a crucial role for circRNAs in the regulation of neonatal myocardial regeneration.
Midface Skeletal Sexual Dimorphism: Lessons Learned from Advanced Three-dimensional Imaging in the White Population
Abushehab, Abdallah, Rames, Jess D. , Hussein, Sara , Pazelli, Alexandre Meira, Sears, Tori A., Wentworth, Adam, Morris, Jonathan M. , Sharaf, Basel , Hussein, Sara M., Meire Pazelli, Alexandre, Sharaf, Basel A, Sharaf, Basel A

Plastic and Reconstructive Surgery - Global Open | October 9, 2024 | Volume: 12 | Issue: 10 | Pages: e6215

10.1097/gox.0000000000006215 | PMID 39386100 Get It

Background: Facial shape is significantly influenced by the underlying facial bony skeleton. Sexual dimorphisms in these structures are crucial for craniofacial, aesthetic, and gender-affirming surgery. Previous studies have examined the orbits and upper face, but less is known about the midface. This study aimed to elucidate the sexual dimorphism in the midface region, focusing on the maxilla and zygomatic bones. Methods: A retrospective review was conducted using facial computed tomography scans from 101 White patients aged 20–79 years, using Materialise Mimics and 3-Matics for segmentation and 3D reconstruction. Measurements and statistical shape modeling of the midfacial skeleton were performed. Results: Our results show a distinct sexual dimorphism in the midfacial skeletal structure across all age groups. Women typically had a narrower bizygomatic width by 1.5 mm (P = 0.04), a shallower maxillary depth by 1.6 mm (P < 0.01), and a midfacial vertical height that was 4 mm shorter than that of men (P = 0.018). In contrast, men exhibited a greater distance between the frontozygomatic sutures by 5.4 mm (P < 0.01), a 3-mm greater interorbitale distance (P < 0.01), and a 2.1-mm wider infraorbital foramina distance (P = 0.007). There were no significant differences in the pyriform and maxillary angles (P = 0.15 and P = 0.52, respectively). Conclusions: Our analysis of midfacial skeletal anatomy revealed sexual dimorphism differences. Men exhibited more pronounced facial features than women, with a broader horizontal midfacial skeleton, a longer midfacial vertical height, and greater maxillary depths compared with women.
Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli
Tchétché, Didier , Blackman, Daniel J. , Khalil, Ramzi F., Möllmann, Helge , Abdel‐Wahab, Mohamed , Ali, Walid Ben, Mahoney, Paul, Ruge, Hendrik, Lin, Lang, Byku, Isida , Gillam, Linda D. , Petronio, Anna Sonia , Attizzani, Guilherme F. , Batchelor, Wayne , Gada, Hemal, Rovin, Joshua D. , Benton, Stewart M., Gardner, Blake, Padang, Ratnasari , Herrmann, Howard C., Ruge, Hendrik , Ali, Walid Ben , Mehran, Roxana , Khalil, Ramzi F. , Bleiziffer, Sabine , Szerlip, Molly , Grubb, Kendra J , Guerrero, Mayra , Rogers, Toby , Whisenant, Brian K. , Althouse, Andrew D. , Herrmann, Howard C.

JAMA Cardiology | October 9, 2024 | Volume: 9 | Issue: 12 | Pages: 1106

10.1001/jamacardio.2024.3241 | PMID 39382856 Get It

Importance Historically, women with aortic stenosis have experienced worse outcomes and inadequate recognition compared to men, being both underdiagnosed and undertreated, while also facing underrepresentation in clinical trials. Objective To determine whether women with small aortic annuli undergoing transcatheter aortic valve replacement have better clinical and hemodynamic outcomes with a self-expanding valve (SEV) or balloon-expandable valve (BEV). Design, Setting, Participants The Small Annuli Randomized to Evolut or SAPIEN Trial (SMART) was a large-scale randomized clinical trial focusing on patients with small aortic annuli undergoing transcatheter aortic valve replacement, randomized to receive SEVs or BEVs and included 716 patients treated at 83 centers in Canada, Europe, Israel, and the US from April 2021 to October 2022. This prespecified secondary analysis reports clinical and hemodynamic findings for all 621 women enrolled in SMART. Data for this report were analyzed from February to April 2024. Interventions Transcatheter aortic valve replacement with an SEV or a BEV. Main Outcomes and Measures The composite coprimary clinical end point comprised death, disabling stroke, or heart failure–related rehospitalization. The coprimary valve function end point was the incidence of bioprosthetic valve dysfunction, both assessed through 12 months. Secondary end points included the incidence of moderate or severe prosthesis-patient mismatch. Results A total of 621 women (mean [SD] age, 80.2 [6.2] years; 312 randomized to the SEV group and 309 to the BEV group) were included in the present analysis. At 12 months, there were no significant differences in the coprimary clinical end point between the SEV and BEV groups (9.4% vs 11.8%, absolute risk difference −2.3%; 95% CI −7.2 to 2.5, P = .35). However, SEV implantation was associated with less bioprosthetic valve dysfunction (8.4% vs 41.8%; absolute risk difference, −33.4%; 95% CI, −40.4 to −26.4; P &amp;lt; .001). SEV implantation resulted in lower aortic valve gradients and larger effective orifice areas at 30 days and 12 months and less mild or greater aortic regurgitation at 12 months compared to BEV implantation. Prosthesis-patient mismatch was significantly lower with SEVs, regardless of the definition used and adjustment for body mass index. Use of SEVs was associated with better quality of life outcomes as assessed by the Valve Academic Research Consortium-3 ordinal quality of life measure. Conclusions and Relevance Among women with severe symptomatic aortic stenosis and small aortic annuli undergoing transcatheter aortic valve replacement, the use of SEVs, compared to BEVs, resulted in similar clinical outcomes and a markedly reduced incidence of bioprosthetic valve dysfunction through 12 months, including a lower risk of prosthesis-patient mismatch and better 12-month quality of life. Trial Registration ClinicalTrials.gov Identifier: NCT04722250
Gender and Racial Demographic Trends in the US Laryngology Workforce (1993–2022)
Parikh, Neil U. , Shuman, Elizabeth A. , Johns, Michael M. , Meratı, Albert L., Zheng, Melissa , Parikh, Neil , Shuman, Elizabeth

The Laryngoscope | October 9, 2024 | Volume: 135 | Issue: 2 | Pages: 794-800

10.1002/lary.31819 | PMID 39381931 Get It

ObjectivesTo analyze demographic trends in laryngology fellowship training in the United States from 1993 to 2022, comparing periods before and after formalization of the fellowship within the National Resident Matching Program (NRMP) in 2012.MethodsA national database of fellowship‐trained laryngologists (FTLs) and non‐fellowship‐trained laryngologists (nFTLs) practicing primarily laryngology was created by methodically compiling laryngologists via Internet search, with corroboration by regional laryngologists and vetting by senior laryngologists on this manuscript. Demographic variables included residency and/or fellowship graduation year, gender, race and ethnicity inferred through individuals' photos and surnames. NRMP match data from 2012 to 2022 were obtained from the American Laryngological Association.ResultsAn average of 21 programs offered 23 positions in the NRMP match, with 14 programs (66.4%) filling 16 positions (68.8%) from 2012 to 2022. The 10‐year FTL growth rate decreased from 25.4% (1993–2002) to 10.5% and 6.6% in subsequent periods. In May 2023, there were 349 active laryngologists, including 303 FTLs, in the United States. A total of 189 (62.4%) FTLs were men, 114 (37.6%) were women; 201 (66.2%) were White, 102 (33.8%) were non‐White. Between the pre‐NRMP and post‐NRMP periods, the percentage of male FTLs decreased from 71.5% to 55.5%, female FTLs increased from 28.5% to 44.5%, and White FTLs decreased from 69.2% to 64.2%. Chi‐squared analysis yielded a statistically significant association between gender and training period for FTLs (p = 0.004), but no statistically significant difference between race and training period.ConclusionsThe post‐NRMP period saw an expansion of laryngology fellowships and workforce diversification, reflecting trends observed in otolaryngology and medicine overall.Level of EvidenceNA Laryngoscope, 135:794–800, 2025
Optimizing Knee Positioning During Arthroscopic Knee Surgery
Ren, Ye , Wan, Rou , Zhang, Jinming , Liao, Kele, Zhao, Chunfeng , Liao, Kele, Zhao, Chunfeng, Zhu, Wentao

Arthroscopy Techniques | October 9, 2024 | Volume: 14 | Issue: 2 | Pages: No page available

10.1016/j.eats.2024.103214 | PMID 40041320 Get It

Abstract: In knee arthroscopy procedures, maintaining the opening of the medial compartment requires an assistant. Creating the posterior portal in knee arthroscopy is also a challenge because of the shape changes of the thick muscle. The leg is usually placed on the surgical bed, is angled off the lateral aspect of the bed, or drapes over the surgical bed in which the leg plates are removed. However, the aforementioned positions have some limits because of surgical convenience and procedural stability. In this Technical Note, we propose an approach to improve the existing knee positions using a metal round stool as a foot support. The method aims to reduce reliance on human assistants during knee arthroscopy procedures and restore the natural positioning of leg muscles, potentially improving procedural outcomes. Technique Video video See video under supplementary data.
Vascular Disease Patient Information Page: Erythromelalgia
Ratchford, Elizabeth V , Solomon, Alexandra , Davis, Mark D. P. , Solomon, Alexandra L , Davis, Mark DP., Davis, Mark D.P.

Vascular Medicine | October 9, 2024 | Volume: 29 | Issue: 6 | Pages: 735-738

10.1177/1358863x241285533 | PMID 39380163 Get It

Behind the curtain: conflicts of interest in spinal cord stimulation trials—an infographic
D’Souza, Ryan S. , Klasova, Johana, Hussain, Nasir , D'Souza, Ryan S

Regional Anesthesia & Pain Medicine | October 8, 2024 | Volume: 51 | Issue: 2 | Pages: 218-218

10.1136/rapm-2024-106069 | PMID 39379325 Get It

Distinguishing Prodromal Dementia With Lewy Bodies From Prodromal Alzheimer Disease
Wyman‐Chick, Kathryn A , Ferman, Tanis J. , Weintraub, Daniel , Armstrong, Melissa J. , Boeve, Bradley F. , Chrenka, Ella , Barrett, Matthew J. , Bayram, Ece , Chrenka, Ella , Barrett, Matthew J , Boeve, Brad , Ferman, Tanis J , Armstrong, Melissa J , Bayram, Ece

Neurology Clinical Practice | October 8, 2024 | Volume: 15 | Issue: 1 | Pages: No page available

10.1212/cpj.0000000000200380 | PMID 39399551 Get It

Drug treatments to prevent first decompensation in cirrhosis
Kezer, Camille A. , Berzigotti, Annalisa , Fortune, Brett E. , Kezer, Camille , Simonetto, Douglas A.

Hepatology | October 8, 2024 | Volume: 83 | Issue: 6 | Pages: 1589-1608

10.1097/hep.0000000000001117 | PMID 39378416 Get It

Cirrhosis is a prevalent condition affecting more than 100 million people globally and carrying significant morbidity and mortality related to the development of portal hypertension and hepatic decompensation. Current treatment is primarily targeted at identifying chronic liver disease early and preventing the progression of fibrosis by treating the underlying etiology of liver disease. Treatment options for patients with advanced fibrosis are limited, and the only drug class approved for the prevention of hepatic decompensation remains nonselective beta-blockers. There are several pharmacological therapies being developed in both preclinical and clinical trials to explore their efficacy in preventing first hepatic decompensation. Most studies evaluate primary endpoints reflective of disease severity and portal hypertension, such as changes in HVPG or fibrosis stage based on histology or imaging. While many drugs are being investigated, much work is still needed to identify treatment targets with effective outcomes to move the needle in the field of cirrhosis management. This narrative review will address the current state of cirrhosis therapies, including potential new therapeutic targets, and provide direction on future advancements that will improve our current treatment paradigm and lead to better outcomes for those burdened with cirrhosis.
Early Renal Outcomes Following Heart Transplantation Using Organs Procured After Circulatory Death
Zhou, Joyce , Sise, Meghan E. , Drezek, Kamila , Wolfe, Stanley B. , Osho, Asishana A. , Prario, Monica N. , Rabi, S. Alireza , Michel, E., Tsao, Lana, Coglianese, Erin , Doucette, Meaghan, Newton‐Cheh, Christopher , Thomas, Sunu, Sutaria, Nilay, Schoenike, Mark, Christ, Anastasia M. , Villavicencio, Mauricio A. , Madsen, Joren C. , Pierson, Richard N. , D’Alessandro, David A. , Zhou, Joyce C , Ton, Van-Khue , Christ, Anastasia M , Paneitz, Dane C , Villavicencio, Mauricio, Madsen, Joren C , Pierson, Richard , Lewis, Gregory D , D'Alessandro, David A , Zlotoff, Daniel A , Wolfe, Stanley , Osho, Asishana , Michel, Eriberto , Ton, Van‐Khue , Lewis, Gregory D.

Journal of the American Heart Association | October 8, 2024 | Volume: 13 | Issue: 20 | Pages: No page available

10.1161/jaha.124.035443 | PMID 39377217 Get It

Background Transplantation using hearts obtained through donation after circulatory death (DCD) is increasing, but data on recipient renal outcomes are limited. Methods and Results Patients at a single institution who underwent heart transplantation using organs procured through DCD or donation after brain death (DBD) from April 2016 to August 2022 were included in this retrospective cohort study. Hemodynamic measures were collected via right heart catheterization performed 1 week after transplantation. Posttransplantation renal outcomes included estimated glomerular filtration rate at 1 week, 4 weeks, and 16 weeks, and the incidence of acute kidney injury (AKI) and renal replacement therapy within 1 week. The analysis included 225 patients (55 recipients of DCD). Baseline characteristics were comparable between recipients of DCD and DBD. Renal outcomes within 1 week posttransplantation in recipients of DCD were similar to recipients of DBD, including percent change in estimated glomerular filtration rate (−37.9% [−58.6 to −6.2] versus −31.9% [−52.4 to −9.9]; P =0.91), incidence of AKI (47.3% versus 46.5%; P >0.99) and incidence of renal replacement therapy (3.6% versus 4.7%; P >0.99). Recipients of DCD with AKI within 1 week (“early AKI”) did not recover to baseline estimated glomerular filtration rate (75.8 [60.2–91.3] mL/min per 1.73 m 2 ) by week 16 (59.3 [46.9–73.6] mL/min per 1.73 m 2 ; P =0.002), whereas recipients without early AKI exhibited comparable estimated glomerular filtration rate to baseline by week 4 (84.5 [70.8–98.5] mL/min per 1.73 m 2 ; P =0.084). Similar trends were observed in recipients of DBD. Conclusions Recipients of DCD demonstrated similar renal outcomes compared with recipients of DBD, supporting the ongoing use of DCD transplantation. Early AKI was associated with persistent renal dysfunction for recipients of both DCD and DBD.